DeCure for Linear skin defects with multiple congenital anomalies
DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for linear skin defects with multiple congenital anomalies — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLinear skin defects with multiple congenital anomalies maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for linear skin defects with multiple congenital anomalies is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cytochrome c oxidase subunit 7B (COX7B) — COX7B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet peedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9I6F · 2.95 Å · ligand 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (PEE). Experimental structure, not a prediction.
What the evidence adds up to
A 2010 study identified a point mutation in the CHUK gene (also called IκB kinase α) in two affected fetuses with a lethal syndrome of multiple malformations, including a defective face and limbs that appeared absent because they were bound to the trunk and encased under the skin. The loss of CHUK disrupts development of skin epidermis and its derivatives. No treatment or intervention was tested in that study.
Two case reports from 2021 describe isolated aplasia cutis congenita (congenital skin defects, especially on the scalp) as difficult to detect before birth but carrying a good prognosis. The authors mention conservative treatment and surgery as options, with choice depending on the individual patient. No drug or molecular therapy is discussed.
A 1993 case report describes covering a myelomeningocele defect in a surviving twin using skin from a stillborn co-twin, with long-term graft healing. Genetic studies were not available, but the twins’ similar anomalies suggested monozygosity. This is a surgical technique, not a drug treatment, and does not address the CHUK-related syndrome.
A 2004 report describes two unrelated female patients with single focal skin defects, unilateral microphthalmia, and limb anomalies, with normal growth and psychomotor development and no brain malformation. The authors suggest these features might be a mild variant of Goltz syndrome or a previously undescribed syndrome. No treatment or drug is tested or proposed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 2010 · 65 citations · open access
Mutant<i>CHUK</i>and Severe Fetal Encasement Malformation
AbstractWe report an autosomal recessive lethal syndrome characterized by multiple fetal malformations, the most obvious anomalies being the defective face and seemingly absent limbs, which are bound to the trunk and encased under the skin. We identified the molecular defect that causes this syndrome, using a combined strategy of gene-expression arrays, candidate-gene analysis, clinical studies, and genealogic investigations. A point mutation in two affected fetuses led to the loss of the conserved helix–loop–helix ubiquitous kinase (CHUK), also known as IκB kinase α. CHUK has an essential role in the development of skin epidermis and its derivatives, along with various other morphogenetic events. (Funded by the Academy of Finland and others.).
Clinical Case Reports · 2021 · 4 citations · open access
Isolated aplasia cutis congenita: A report of two cases
AbstractCongenital skin dysplasia, especially isolated scalp defects, is difficult to detect prenatally. The prognosis for isolated congenital scalp defects is good. Treatment options include conservative treatment and surgery. The choice of treatment depends on the patient's individual circumstances.
Closure of Myelomeningocele Using Skin from Stillborn Twin
AbstractWe report a case of homologous skin transplantation from a stillborn twin to the surviving twin for coverage of a myelomeningocele defect. Genetic studies were not available preoperatively, however, similar morphogenetic anomalies of the twins suggested monozygosity. Long-term follow-up revealed a well-healed graft. Cutaneous genetics and literature review of twin homologous skin transplantation are presented.
Focal skin defect, limb anomalies and microphthalmia
AbstractWe describe two unrelated female patients with congenital single focal skin defects, unilateral microphthalmia and limb anomalies. Growth and psychomotor development were normal and no brain malformation was detected. Although eye and limb anomalies are commonly associated, clinical anophthalmia and limb defects have not been reported with single focal aplasia of the skin. The described features may be compatible with a mild phenotypic variant of Goltz syndrome or may represent a previously undescribed syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
